Will your insurance cover a GLP-1?

Why there is no single price

People search for “the cost of Ozempic” expecting one number, and there isn’t one. The same medication, from the same pharmacy, on the same day, can cost two people wildly different amounts. Four things drive that gap:

• What the drug is approved to treat. The single biggest factor. Ozempic and Mounjaro are approved for type 2 diabetes; Wegovy and Zepbound are approved for chronic weight management. Insurers treat those two categories very differently, and many plans that readily cover a diabetes medication exclude weight-management medications entirely.
• Your insurance type. Commercial, Medicare, Medicaid, or none — each puts you on a different pathway with different rules, as the tool above sets out.
• Your specific plan’s formulary. Two people with commercial insurance from different employers can face completely different costs for the same drug.
• Which savings programmes you can use. This is where the largest avoidable losses happen, because the eligibility rules are counterintuitive.

If your plan does not cover it, the list price is not what you pay either

A denial is not the end of the question, because the list price a plan is refusing to cover is not the price a person pays cash. Both manufacturers now sell direct at a substantial discount — the gap between a published list price and a published self-pay price runs to several hundred dollars a month for the identical product.

We do not repeat those figures here, because they belong on one page rather than two and they change often enough that a second copy would eventually disagree with the first. Every route is priced side by side, with telehealth membership fees added to medication rather than advertised separately, in the comparison of what each way of paying actually costs. What this page answers is the question before that one: whether you have to pay cash at all.

The savings-card rule that catches people out

If that applies to you, the routes that remain are genuinely different in kind: the Medicare GLP-1 Bridge programme described below, patient-assistance programmes run by manufacturers (means-tested, and separate from savings cards), Medicare’s Extra Help programme, and state pharmaceutical assistance programmes.

The Medicare GLP-1 Bridge programme

This is new and significant. Since 1 July 2026, eligible Medicare Part D enrollees can get certain weight-management GLP-1s for a flat $50 per month through a programme called the Medicare GLP-1 Bridge. That matters because Part D has historically been unable to cover medications prescribed solely for weight loss.

• Covered: Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet).
• Not covered: Zepbound single-dose pens and Zepbound vials — the formulation matters, so check which one your prescription specifies.
• To qualify: enrolment in a participating Part D plan, a BMI of 35 or higher (or 27 or higher with a qualifying related condition), and prior authorisation.

Three caveats that are easy to miss, and each of them costs money:

• Plan participation is voluntary. Your Part D plan may simply not take part, so ask before assuming.
• The $50 does not count toward your Part D deductible or your annual out-of-pocket cap.
• Low-income subsidies cannot be applied to bridge-programme prescriptions.

It is also a time-limited programme with a successor model planned, so confirm the current end date and your plan’s participation directly with Medicare and your plan rather than relying on any published summary, including this one.

If your claim is denied

A denial is a starting position, not a verdict. Prior-authorisation denials are frequently overturned on appeal when the prescriber supplies clinical documentation — your diagnosis, previous treatments tried, comorbidities, and why this medication is appropriate. Ask your prescriber’s office directly whether they will file an appeal; many have staff who do this routinely.

Practical points that improve the odds:

• Ask for the denial reason in writing — the specific criterion you failed matters.
• Ask what the plan’s documented approval criteria actually are, then address them point by point.
• Ask whether a formulary exception or a step-therapy exception is the right route.
• Note the appeal deadline, which is usually strict.

A warning about unusually cheap sources

Questions worth asking before you start

Cost is a legitimate part of a treatment decision, not a separate administrative matter. Because these medications generally need to be taken long-term to maintain their effect, affordability over months and years matters more than the first month’s price. Worth raising with your prescriber:

• Is there an alternative in this class my plan covers better?
• If my savings card has a cap or expiry, what happens to my cost after that?
• What happens if I have to stop for cost reasons — and what should I expect?

On that last point, the appetite effect depends on the drug still being in your system — so stopping for cost reasons generally means appetite returns.

More cost guides

If price is the constraint rather than coverage, the companion guide takes the same question from the other end: the cheapest way to get a GLP-1 prices every route side by side — insurance, Medicare, buying direct from the manufacturer, and online telehealth providers with their membership fees added to the medication rather than advertised separately.

If you already know which medication you are asking about, the question stops being about routes and becomes about forms — which versions of that drug exist and who supplies them. Those have an answer each: semaglutide is the one you can buy as a tablet, which shares the lowest published price for any approved product in the class with the other tablet in it, while tirzepatide has no tablet to fall back on and is priced from the injection up.

Further guides on coverage appeals and comparing costs across the class are being written and will be linked here as they are published.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.